Results 71 to 80 of about 10,024 (235)

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the united kingdom randomised, controlled open-label, platform adaptive trial [PDF]

, 2022
Background: The safety, effectiveness and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, in patients in the community who are multiply-vaccinated and at increased risk of morbidity and mortality from COVID-19, has not ...
Allen, Julie, Andersson, Monique, Barrett, Sarah, Bateman, Clare, Benysek, Magdalena, Berry, Nicholas, Breuer, Judith, Butler, Christopher, Butler, Daniel, Carson-Stevens, Andrew, Chalk, Jeremy, Coates, Maria, Cureton, Lucy, Davies, Jennifer, Detry, Michelle, Dobson, Melissa, Dorward, Jienchi, Evans, Philip, Fitzgerald, Mark, Francis, Nick, Galal, Ushma, Gbinigie, Oghenekome, Hadley, Elizabeth, Harris, Victoria, Hart, Nigel, Hayward, Gail, Hobbs, Richard, Holmes, Jane, Hood, Kerenza, Jani, Bhautesh, Khoo, Saye, Lavallee, Layla, Little, Paul, Lowe, David, Lown, Mark, Madden, Tracie-Ann, Marion, Joe, Mwandigha, Lazaro, Nguyen-Van-Tam, Jonathan S, Ogburn, Emma, Patel, Mahendra, Petrou, Stavros, Png, May Ee, Rahman, Najib M, Raymundo-Wood, Ivy, Richards, Duncan, Rutter, Heather, Saunders, Christina, Saville, Benjamin R, Standing, Joseph F, Thomas, Nicholas, Ustianowski, Andrew, van Hecke, Oliver, Yu, Ly-Mee   +53 more
core   +2 more sources

Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients

Viruses, 2022
Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient molnupiravir use in kidney transplant recipients and hemodialysis patients
Paweł Poznański, Hanna Augustyniak-Bartosik, Anna Magiera-Żak, Karolina Skalec, Katarzyna Jakuszko, Oktawia Mazanowska, Dariusz Janczak, Magdalena Krajewska, Dorota Kamińska   +8 more
doaj   +1 more source

Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study. [PDF]

, 2022
As of October 2021, neither established agents (e.g., hydroxychloroquine) nor experimental drugs have lived up to their initial promise as antiviral treatment against SARS-CoV-2 infection.
Chaccour, Carlos, Hammann, Felix, Kern, Charlotte, Schöning, Verena   +3 more
core   +1 more source

Buyer beware: molnupiravir may damage DNA [PDF]

BMJ, 2021
Although the Ingelfinger rule seems to have dissolved into dust with the coming of covid-19,1 I was a little disappointed that your journal seems to have mirrored Merck’s press release about molnupiravir without substantial critical comment.2 Molnupiravir …
openaire   +2 more sources

Population-Based Propensity Score-Matched Analysis of Paxlovid and Molnupiravir Effectiveness in High-Risk COVID-19 Patients

International Journal of Infectious Diseases
Introduction: COVID-19 poses a severe threat to high-risk populations, such as the elderly and those with incomplete vaccination. Despite the availability of treatments like Paxlovid and Molnupiravir, their relative effectiveness in preventing severe ...
Dr Yi-hsuan Chen, Dr Cheng-Yi Lee, Dr Hao-Yuan Cheng, Mr. Yu-Neng Cheuh, Mr. Hung-Wei Kuo   +4 more
doaj   +1 more source

Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study [PDF]

, 2023
Purpose: To investigate the clinical impact of three available antivirals for early COVID-19 treatment in a large real-life cohort. Methods: Between January and October 2022 all outpatients tested positive for SARS-CoV-2 referring to IRCCS S.
Bonazzetti C., Campoli C., Casarini M., Curti S., Gallo M., Giannella M., Malosso M., Marconi L., Marzolla D., Pascale R., Pasquini Z., Riccardi R., Riccucci D., Rinaldi M., Tazza B., Viale P., Zuppiroli A.   +16 more
core   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source

Successful in vitro propagation of feline coronavirus from clinically diagnosed feline infectious peritonitis cases using Vero cells: A potential model for future research

Veterinary Record Open, Volume 13, Issue 1, June 2026.
Abstract Background Feline coronavirus (FCoV) causes inapparent to progressive fatal feline infectious peritonitis (FIP) in domestic and wild cats, which affects multiple‐organ systems. Methods We investigated three clinically sick cats using different laboratory and molecular tests to diagnose and confirm FCoV and propagate the virus in Vero cell ...
Eaftekhar Ahmed Rana, Mahfuza Akther, Susan Beetson, Subir Sarker, Gabriele Rossi, Jasim M. Uddin   +5 more
wiley   +1 more source

Antivirals Targeting Coronavirus RNA‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID‐19 Clinical Trials

Microbial Biotechnology, Volume 19, Issue 4, April 2026.
The target sites of COVID‐19 antivirals discussed in the present opinion paper, namely the RNA dependent RNA polymerase Nsp12 and of the main viral protease Nsp5, are indicated by a red star in the overview of the replication cycle of coronavirus SARS‐CoV‐2.
Harald Brüssow
wiley   +1 more source

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Infectious Diseases and Therapy, 2023
Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for outpatient treatment of mild-to-moderate COVID-19, significantly reducing the risk of ...
Julie M. Strizki, Jay A. Grobler, Nicholas Murgolo, Arthur Fridman, Matthew G. Johnson, Jiejun Du, Patricia Carmelitano, Michelle L. Brown, Amanda Paschke, Carisa De Anda   +9 more
doaj   +1 more source